FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 9:30 a.m. ET.

Company management will also participate in one-on-one meetings during the conference, which will run from April 8-11, 2024.

To access the live webcast and an archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc. 

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA^® (vonoprazan) tablets for the treatment of Erosive GERD and relief of related heartburn in adults, in addition to VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
This email address is being protected from spambots. You need JavaScript enabled to view it.

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
This email address is being protected from spambots. You need JavaScript enabled to view it.

© 2024 Phathom Pharmaceuticals. All rights reserved.